Halberd (HALB)

Executive Summary

Halberd Corporation is a micro-cap biotech company developing extracorporeal treatment technologies for infectious diseases and neurological disorders. Its patented approach involves physically removing disease-causing agents from blood and cerebrospinal fluid, targeting COVID-19, PTSD, and CTE. The company is publicly traded (HALB) but currently has no disclosed pipeline programs or clinical-stage assets, indicating very early development. Given its minimal valuation (~$636k) and lack of revenue, Halberd faces significant execution risk. However, its novel platform could address unmet needs if successfully validated. Near-term catalysts are unclear, as no specific milestones have been announced; potential events include preclinical data releases or partnering discussions. The company's ability to secure funding and progress toward human trials remains critical.

Upcoming Catalysts (preview)

• 2026Preclinical data release for COVID-19 device10% success
• 2027Regulatory meeting or IND filing for PTSD/CTE program5% success
• 2026Partnership or licensing deal to advance technology20% success